Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq analysis of H69 cholangiocyte cell line stimulated with imidazole propionate

ABSTRACT: Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the bile ducts associated with inflammatory bowel disease and an altered gut microbiota. Here we studied the transcriptomic impact of the gut microbial metabolite imidazole propionate and its precursor urocanate on a human cholangiocyte cell line.

ORGANISM(S): Homo sapiens

PROVIDER: GSE341409 | GEO | 2026/08/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The microbial metabolite imidazole propionate modulates hypothalamic activity and stress-induced behaviors

Project description:Neural circuits driving mammalian behaviors are highly plastic and modulated by internal and external factors, including the gut microbiome. We identify imidazole propionate (ImP), a microbial metabolite linked to metabolic disorders, as a key modulator of brain activity and behavior. Bacterially derived ImP enters the systemic circulation and brain, where it alters neuronal gene expression and activity in the hypothalamus without inducing overt neuroinflammation. Elevating systemic ImP promotes stress-related pathways and disrupts GABAergic/glutamatergic signaling in the hypothalamus before peripheral glucose dysregulation occurs. Similarly, colonization with the ImP-producing bacterium Eggerthella lenta elevates behavioral and molecular features of stress. In a mouse model of type 2 diabetes, the gut microbiome exhibits an enhanced ability to produce ImP, leading to elevated systemic levels that are associated with heightened stress responses. In humans, higher ImP associates with reduced hypothalamic reactivity to food cues, impaired stress-coping, and increased emotional eating, mirroring the causal links between ImP, hypothalamic activity, and stress-related behaviors in mice. Overall, these findings establish ImP as a notable microbial metabolite that links gut dysbiosis to altered hypothalamic function and stress in metabolic disease.

2025-06-26 | GSE300937 | GEO

Imidazole propionate (ImP): effect on human aortic endothelial cells

Project description:Imidazole propionate (ImP): effect on human aortic endothelial cells

| PRJEB61803 | ENA

RNA sequencing reveals differential MYC-driven gene expression as a driver of a divergent cholangiocyte response to stress

Project description:In Primary Sclerosing Cholangitis (PSC), some cholangiocytes undergo cell cycle arrest (senescence) while others proliferate (ductular reaction). Our aim was to determine the mechanisms driving this divergent response. We used lipopolysaccharide (LPS) to stress normal human cholangiocytes (NHC) transfected with a senescence reporter, p16- promoter driven green fluorescent protein. We performed RNA sequencing to assess gene expression profiles on non-senescent (GFP-) and senescent (GFP+) cholangiocytes. Our analysis revealed a MYC-driven gene expression profile in non-senescent cholangiocytes and suggest that MYC may function as a "molecular switch" in determining cholangiocyte responses to stress.

2025-07-30 | GSE296039 | GEO

Imidazole propionate is a driver and therapeutic target in atherosclerosis [scRNA-seq]

Project description:Atherosclerosis is the main underlying cause of cardiovascular diseases (CVDs). Its prevention is based on traditional cardiovascular risk factor-based scores but often fails to identify individuals at early stages of the disease. Here, we identified microbially produced imidazole propionate (ImP) as an early biomarker of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration induced atherosclerosis without altering lipid metabolism and it was associated with activation of both systemic and local innate and adaptive immunity and inflammation. Here, we used single-cell RNA-seq to characterize the local changes of aorta-derived cells in mice under treatment with ImP for 4 and 8 weeks. Notably, ImP caused atherosclerosis through the Imidazoline-1 receptor (I1R), and the blockade of the ImP/I1R axis inhibited the development of atherosclerosis induced by ImP as well as by high cholesterol diet in mice. Identification of ImP as an early biomarker for atherosclerosis and uncovering the contribution of the ImP/I1R axis in disease progression open new avenues to improve atherosclerosis early diagnosis and therapy.

2025-07-16 | GSE298392 | GEO

Imidazole propionate is a driver and therapeutic target in atherosclerosis [scRNA-seq]

Project description:Imidazole propionate is a driver and therapeutic target in atherosclerosis [scRNA-seq]

| PRJNA1269065 | ENA

The microbial metabolite imidazole propionate modulates hypothalamic activity and stress-induced behaviors

Project description:The microbial metabolite imidazole propionate modulates hypothalamic activity and stress-induced behaviors

| PRJNA1282701 | ENA

Host sensing of microbially produced imidazole propionate is a driver and therapeutic 1 target in atherosclerosis

Project description:Atherosclerosis is the main underlying cause of cardiovascular diseases (CVDs). Its prevention is based on the detection and treatment of traditional cardiovascular risk factors1 but often fails to identify individuals at risk for early vascular disease2. Recent research has suggested new players in the pathophysiology of atherosclerosis3, highlighting the need for alternative disease biomarkers and therapeutic targets to improve early diagnosis and therapy efficacy. Here, we identified that microbially produced imidazole propionate (ImP) is associated with the extent of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration to atherosclerosis-prone mice fed chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and it was linked to activation of both systemic and local innate and adaptive immunity and inflammation. Specifically, we found that ImP caused atherosclerosis through Imidazoline-1 receptor (I1R) expressed in myeloid cells. Blocking this ImP/I1R axis inhibited the development of atherosclerosis induced by ImP as well as by high cholesterol diet in mice. Identification of the strong association of ImP with active atherosclerosis, along with the discovery of the contribution of the ImP/I1R axis to disease progression opens new avenues for improving the early diagnosis and personalized therapy of atherosclerosis.

2025-09-15 | PXD063955 | Pride

Imidazole propionate is an early biomarker and therapeutic target for atherosclerosis [bulk RNA-seq]

Project description:Atherosclerosis is the main underlying cause of cardiovascular diseases (CVDs). Its prevention is based on traditional cardiovascular risk factor-based scores but often fails to identify individuals at early stages of the disease. Here, we identified microbially produced imidazole propionate (ImP) as an early biomarker of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration induced atherosclerosis without altering lipid metabolism and it was associated with activation of both systemic and local innate and adaptive immunity and inflammation. Notably, ImP caused atherosclerosis through the Imidazoline-1 receptor (I1R), and the blockade of the ImP/I1R axis inhibited the development of atherosclerosis induced by ImP as well as by high cholesterol diet in mice. Here, we profiled three cell lines which represent cell types typically found in aortas (bone marrow-derived macrophages, mouse embryonic fibroblasts and mouse aortic endothelial cells) upon in vitro stimulation with ImP at different time points to better understand the transcriptional regulation of the ImP/I1R axis and its role in the development of the disease. Identification of ImP as an early biomarker for atherosclerosis and uncovering the contribution of the ImP/I1R axis in disease progression open new avenues to improve atherosclerosis early diagnosis and therapy.

2025-07-16 | GSE297831 | GEO

6d989d11-209a-4dcf-b685-cb900bf341eb - samples

Project description:Intrahepatic cholangiocyte organoid clone from patients with chronic alcohol consumption, NASH (nonalcoholic steatohepatitis), and PSC (primary sclerosing cholangitis)

| EGAD00001007775 | EGA

Affect of Aramchol on TGFβ stimulated H69 Cholangiocytes

Project description:Cholestatic liver diseases, such as primary sclerosing cholangitis (PSC), are characterized by biliary fibroinflammation. Transforming growth factor-β (TGFβ) activated cholangiocytes release signals that recruit immune cells to drive inflammation and activate myofibroblasts to deposit the extracellular matrix (ECM). TGFβ regulates stearoyl-CoA desaturase (SCD) in stimulating lipid signaling. However, the role of SCD or its inhibitor, Aramchol, has not been investigated in biliary fibroinflammation. Here we used human transformed H69 cholangiocytes that were treated with TGFβ (10ng/mL) with and without Aramchol acid (30µM) overnight. RNA-seq analysis showed significant inhibition of TGFβ-induced hepatic fibrosis pathways while upregulating peroxisome proliferator-activated receptor (PPAR) signaling by Aramchol.

2025-07-23 | GSE303012 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data